TK216 in Patients With Relapsed or Refractory Ewing Sarcoma

NCT02657005 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

85

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

Sarcoma, Ewing

Interventions

DRUG: TK216

Sponsor

Oncternal Therapeutics, Inc